aTyr Pharma, Inc. (NASDAQ: LIFE) spotted trading -41.46% off 52-week high price. On the other end, the stock has been noted 113.77% away from the low price over the last 52-weeks. The stock changed -0.34% to recent value of $5.9. The stock transacted 41161 shares during most recent day however it has an average volume of 243.12K shares. The company has 3.77M of outstanding shares and 3.58M shares were floated in the market.
aTyr Pharma, Inc. (LIFE) recently reported third quarter 2019 results and provided a corporate update.
Third Quarter 2019 and Subsequent Period Highlights
Continued to advance its ongoing Phase 1b/2a clinical trial of ATYR1923 in patients with pulmonary sarcoidosis, with interim safety data predictable by year-end.
Reported a research alliance with Dr. Diane Bielenberg, an expert in NRP2 biology, and Boston Children’s Hospital to examine the therapeutic efficacy of anti-NRP2 antibodies in potential new roles and indications. Dr. Bielenberg’s research will initially explore conditions characterized by inappropriate smooth muscle contractility, such as urinary incontinence and gastrointestinal tract motility disorders, where current treatments often have limited efficacy and serious side effects.
Supported both the World Association for Sarcoidosis and Other Granulomatous Disorders (WASOG) and the Japan Society of Sarcoidosis and other Granulomatous Disorders (JSSOG) as a key sponsor of the Joint Conference of WASOG’s International Conference on Sarcoidosis and Interstitial Lung Diseases 2019 and The 39th Yearly Meeting of JSSOG held in Yokohama, Japan in October.
Continued to strengthen intellectual property portfolio with patent applications filed covering our lead monoclonal NRP2 antibodies.
Reported that leading immunology researcher Dr. David Briscoe joined the company as scientific advisor.
Third Quarter 2019 Financial Results and Cash Position
Net loss for the three and nine months ended September 30, 2019 was $5.6M and $17.6M, or $1.47 per share and $5.55 per share, respectively, contrast to $7.1M and $28.2M, or $3.33 per share and $13.22 per share, for the same periods in 2018, respectively. Net loss for the three and nine months ended September 30, 2019 reflects cost savings associated with the program prioritization and corporate restructuring reported in May 2018. Historical and current period net loss per share values have been adjusted to reflect the Company’s June 2019 reverse stock split.
As of September 30, 2019, aTyr had $38.1M in cash, cash equivalents and investments.
For the nine months ended September 30, 2019, cash burn, net of debt and equity, was $14.8M. For the year ending 2019, aTyr is maintaining its previous guidance that total cash burn will be at the lower end of the company’s before guided range of $23M to $25M, net of debt and equity.
According to the most recent quarter its current ratio was 3.3 that represents company’s ability to meet its current financial obligations. The price moved ahead of 8.48% from the mean of 20 days, 26.32% from mean of 50 days SMA and performed 23.78% from mean of 200 days price. Company’s performance for the week was -16.43%, 41.15% for month and YTD performance remained 41.49%.